BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)

Health Canada Approves BioSyent's Thyconvi for Hypothyroidism

BioSyent Inc. announced that Health Canada has approved Thyconvi™ (levothyroxine sodium), establishing it as the first and only levothyroxine oral solution available in Canada. This approval covers the management of hypothyroidism across various etiologies and states, including pregnancy, and for thyroid-stimulating hormone (TSH) suppression in well-differentiated papillary or follicular thyroid carcinoma. BioSyent Pharma Inc., a subsidiary, holds exclusive rights for marketing and distribution in Canada. The company anticipates launching the product in the coming months, aiming to address an unmet medical need for a convenient liquid formulation.

• Thyconvi™ represents a significant advancement in hypothyroidism care by offering an oral liquid formulation. This is particularly beneficial for patient populations who experience difficulties with solid doses, facilitating consistent daily dosing and providing enhanced flexibility for therapy titration to achieve target TSH levels.
• The approval encompasses broad indications, including its use as replacement or supplemental therapy for primary, secondary, and tertiary hypothyroidism of any etiology and in any state, including pregnancy. It is also approved as an adjunct to surgery and radioactive iodine therapy for TSH suppression in thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid.
• Thyconvi™ is an oral liquid dosage containing 20 micrograms of levothyroxine sodium per millilitre. It is supplied in a package of two 75 mL bottles and offers significant convenience as it does not require refrigeration, simplifying storage and accessibility for patients and healthcare providers.

Addressing Key Unmet Needs in Hypothyroidism Management

Recent literature highlights several critical unmet needs in hypothyroidism management, with specific vulnerable populations requiring targeted therapeutic approaches. These gaps reflect both demographic disparities in treatment access and clinical challenges in achieving optimal patient outcomes despite current standard therapies.

• Elderly patients with subclinical hypothyroidism - More than 10-15% of people aged over 80 years are prescribed levothyroxine, yet minor TSH elevations in this population are not associated with important outcomes such as impaired quality of life, symptoms, cognition, cardiovascular events, or mortality

• Patients with persistent symptoms despite normalized TSH levels - Some patients continue to experience fatigue, mood disturbances, and poor quality of life despite adequate LT4 dosing, as LT4 monotherapy may not fully restore T3 levels, leading to suboptimal symptom control

• Reproductive-aged women, particularly uninsured patients - Less than 50% of reproductive-aged women in the NHANES dataset received treatment, with treatment rates dropping to only 22% among uninsured patients, despite consequences including subnormal fertility, recurrent pregnancy loss, and compromised fetal development

• Cancer patients receiving immunotherapy - Overall incidence of thyroid dysfunction was 2.97% among PD-1 inhibitor recipients, with 77.31% of cases occurring within the first four months of treatment, requiring close monitoring particularly for female patients and those with baseline TgAb positivity

• Inadequately treated patients in real-world practice - Approximately half of patients with hypothyroidism achieve target euthyroidism, with pooled prevalence showing adequate replacement at 55%, over-replacement at 20%, and under-replacement at 24%

• Breast cancer survivors treated with radiotherapy - These patients show 68% higher risk of developing hypothyroidism (HR 1.68; 95% CI 1.42-1.99), particularly those receiving radiation treatment of regional lymph nodes, with median onset at 3.45 years post-treatment

Overcoming Challenges in Hypothyroidism Dosing and Titration

Current hypothyroidism treatment faces significant challenges in achieving optimal patient outcomes and satisfaction. Despite widespread use of levothyroxine monotherapy, substantial gaps remain in treatment effectiveness and patient quality of life. These limitations have prompted investigation into alternative approaches and combination therapies.

• Suboptimal treatment prevalence — 30-50% of individuals on levothyroxine are either over-treated or under-treated, with large numbers of hypothyroid patients remaining suboptimally managed despite therapy

• Persistent patient dissatisfaction — Many patients remain dissatisfied with treatment and report poorer quality of life even when achieving thyroid hormone concentrations within laboratory reference intervals and biochemical euthyroid status

• Poor medication adherence — Overall adherence to levothyroxine is concerning, with 66.7% of patients showing low adherence, 23.3% moderate adherence, and only 10% high adherence levels

• Clinical management complexities — Optimal timing of medication, strategies to overcome treatment non-adherence, and target TSH concentrations in pregnancy and differentiated thyroid cancer patients remain challenging

• Incomplete symptom resolution — Lifelong levothyroxine supplementation has notable limitations and does not fully restore quality of life for many patients, with chronic symptoms failing to respond to conventional treatments in a significant proportion of cases

• Uncertain combination therapy benefits — While combination therapy with liothyronine and levothyroxine shows theoretical promise for genetically predisposed individuals, existing evidence remains limited and benefits are uncertain

• Economic burden — Poor adherence to levothyroxine is linked to significant healthcare costs and economic burdens, while long-term treatment causes many side effects for patients

• Diagnostic limitations — Many people have hypothyroidism that remains undetected by conventional laboratory thyroid-function tests, potentially leaving patients untreated

Thyconvi™: Expanding Options for Diverse Hypothyroidism Patients

Hypothyroidism demonstrates distinct demographic patterns that are critical for clinical management and therapeutic decision-making. The condition exhibits pronounced gender disparities, age-related prevalence trends, and socioeconomic variations that inform targeted treatment approaches.

Gender Distribution:
• Women are disproportionately affected, with 5-10 times higher prevalence than men across all populations studied
• Female prevalence consistently ranges from 7-11% while male prevalence remains at 2-3% globally
• In Iran, women demonstrate five-fold increased odds of developing hypothyroidism (adjusted OR=5.31, 95% CI=3.06-9.19)
• Among levothyroxine users, 83% are female, reflecting the substantial gender disparity in treatment requirements

Age-Related Patterns:
• Prevalence increases substantially with advancing age, particularly in women over 45 years
• In Quebec, prevalence among individuals ≥65 years reaches 21.9% in women and 8.0% in men
• Peak incidence occurs in women aged 45-64 years and men aged ≥65 years
• Women typically develop hypothyroidism between ages 30-39, with prevalence continuing to rise through menopause and beyond

Socioeconomic Demographics:
• Clear inverse relationship exists between income level and hypothyroidism prevalence
• Very low-income populations demonstrate 7.01% prevalence compared to 4.23% in high-income groups
• Unemployment status correlates with higher prevalence (7.35%) versus employed individuals (5.80%)
• These disparities likely reflect differential access to healthcare, nutritional factors, and comorbidity burdens

Geographic and Regional Variations:
• Prevalence varies significantly by geographic location, from 2.1% in Dubai to 9.3% in Iran
• Within regions, environmental factors create substantial variation (coastal vs mountainous areas in Spain: 6.70% vs 8.91%)
• Iodine availability and dietary patterns contribute to regional differences in hypothyroidism burden

Special High-Risk Populations:
• Pregnant women show elevated prevalence (4.8-29% depending on region) with significant obstetric implications
• Patients with Type 1 diabetes demonstrate 9.8% hypothyroidism prevalence, particularly in South America (17.1%)
• Individuals with Down syndrome, PCOS, and other endocrine disorders require enhanced screening protocols

Canada's First Liquid Levothyroxine: Reshaping Hypothyroidism Management

The recent Health Canada approval of Thyconvi™ marks a pivotal moment for patients managing hypothyroidism in Canada. As the first and only levothyroxine oral solution, this product directly addresses a long-standing unmet need for a more convenient and flexible treatment option. For many patients, particularly those with dysphagia, feeding tubes, or those requiring precise dosing like pregnant women, the strict administration requirements of levothyroxine tablets—taking them on an empty stomach, separate from other medications, and at a specific time before food—can be a significant barrier to consistent therapy. Studies have consistently highlighted these challenges, noting that absorption can be impaired by various factors.

The introduction of a liquid formulation, which has demonstrated bioequivalence to tablet forms in clinical research, offers a promising solution. This ensures that patients can achieve similar therapeutic outcomes, including effective TSH suppression and normalization, with potentially greater ease and improved adherence. For BioSyent, this approval establishes a strong market position, providing a unique offering in a therapeutic area where differentiation is often challenging. The company gains a first-mover advantage, allowing it to capture a significant segment of the market seeking alternative delivery methods.

However, the inherent complexities of levothyroxine therapy persist. Even with a liquid formulation, careful consideration must be given to absorption variability, which can be influenced by diet, other medications, and gastric conditions. This necessitates continued individualized dose titration and diligent monitoring to prevent both under- and overtreatment. Furthermore, the stability of levothyroxine sodium, known for its photosensitivity and susceptibility to oxidation, remains a critical factor for any formulation. The risks of overtreatment, particularly in elderly patients with subclinical hypothyroidism where it has been linked to increased mortality, underscore the importance of precise and consistent dosing. While Thyconvi offers a significant step forward in patient convenience and adherence, its successful integration into clinical practice will depend on careful management and ongoing patient education to optimize outcomes and mitigate these known risks.